Fig. 6: Paediatric patients reporting asthma worsenings and adverse events related to asthma exacerbations or symptoms29.
From: Asthma exacerbations and worsenings in patients aged 1–75 years with add-on tiotropium treatment
Comparison of number of patients aged 1–17 years with asthma or persistent asthmatic symptoms receiving either tiotropium (5 or 2.5µg) or placebo once daily reporting (a) asthma worsenings or (b) AEs related to asthma exacerbations or symptoms. The vertical axis represents an equal risk of experiencing an AE related to asthma exacerbations or symptoms when receiving either placebo or tiotropium. HR/RR values <1 demonstrate that tiotropium provides a reduction in risk compared with placebo. An upper CI of <1 demonstrates that the reduction in risk is statistically significant. AE adverse event, CI confidence interval, HR hazard ratio, RR rate ratio. Figure b is from ref. 29. Copyright © 2018. Reprinted with permission.
